Audited Financial results (standalone and consolidated) for half year and year ended on March 31, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 18.8 pts more than Nifty Microcap 250 and 18.4 pts more than its Specialty Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Deepak Chemtex Limited, listed on BSE SME (scrip 544036), reported strong FY25 results with an unmodified audit opinion from Mittal & Associates. Standalone revenue from operations grew ~35% to ₹6,799.68 lakhs (vs ₹5,040.41 lakhs in FY24), while profit after tax jumped ~52% to ₹1,006.95 lakhs (vs ₹663.39 lakhs). On a consolidated basis, revenue surged ~61% to ₹7,944.51 lakhs and PAT more than doubled to ₹1,250.92 lakhs. Basic EPS stood at ₹9.27 (standalone) and ₹11.69 (consolidated). The company operates in a single segment (specialty chemicals/dyes) and has reduced short-term borrowings sharply from ₹154.41 lakhs to ₹2.74 lakhs. Out of ₹2,304 lakhs raised via IPO, ₹921.44 lakhs has been deployed, leaving ₹1,382.56 lakhs still unutilized as of March 31, 2025.
Strong revenue and profit growth, expanding margins, and an unmodified audit opinion signal healthy operational performance for shareholders. However, investors may note the substantial unutilized IPO proceeds and that the consolidated operating cash flow was relatively weak (₹296 lakhs) compared to standalone (₹1,078 lakhs), warranting a watch on working capital and subsidiary-level cash generation.